|Offre||83,42 x 800|
|Vente||84,00 x 1800|
|Var. jour||82,61 - 83,86|
|Sur 52 semaines||75,77 - 95,60|
|Volume moyen||6 022 374|
|Bêta (mensuel sur 5 ans)||0,72|
|Rapport P/E (sur 12 mois)||29,59|
|BPA (sur 12 mois)||2,83|
|Date de bénéfices||25 mai 2023|
|Dividende et rendement à terme||2,76 (3,33 %)|
|Date ex-dividende||22 juin 2023|
|Objectif sur 1 an||91,23|
NORTHAMPTON, MA / ACCESSWIRE / November 9, 2022 / Medtronic In this episode, Mira Sahney, president of the Pelvic Health business at Medtronic, explains how incontinence is a debilitating condition that needs more attention and treatment. The company's ...
CECP's CEO Investor Forum, the only platform that brings CEOs and investors together to discuss Long-Term Plans, hosted three CEOs from the world's largest medtech companies-Abbott (NYSE:ABT), Medtronic (NYSE:MDT), and Intuitive Surgical (NASDAQ:ISRG).
Medtronic Stroke is a leading cause of death and disability around the world, but only a fraction of people who suffer a stroke get treatment in time.
This episode shines a light on lung cancer, a deadly killer that isn't getting the attention it deserves. Dr. William Mayfield, WellStar Health System medical director, and former chief surgical officer says lung cancer kills thousands of people every day - more than most other cancers combined - but isn't screened for as aggressively.
When Ursula Douglas started working for Medtronic in 2015, she remembers being the only woman on her sales team and one of the few women of color working as a Medtronic senior interventional sales representative. In fact, the U.S.
NORTHAMPTON, MA / ACCESSWIRE / October 21, 2022 / Medtronic The premier global organization advocating for LGBTQ+ workplace equality awarded Medtronic with its New Employee Resource Group (ERG) of the Year Award in recognition of the company's bold ...
Medtronic Executive Vice President and Chief Human Resources Officer Carol Surface is the top CHRO in the world for 2022, according to N2 Growth, a global executive search and leadership advisory firm.
La première du genre, cette étude démontre que les personnes utilisant le système de Medtronic ont obtenu une réduction absolue de 1,4 % de l'HbA1c et une augmentation absolue de 27,6 % du temps dans la plageDUBLIN, 1er septembre 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), leader mondial des technologies de la santé, a annoncé aujourd'hui que les résultats de l'étude Medtronic ADAPT ont été publiés dans The Lancet Diabetes & Endocrinology. L'étude ADAPT est la première étude multinationale ra